New human fusion partners, ICLU-B, -T, -E for making human hybridomas derived from various immunological cells.

To investigate human immune responses, it is useful to use cultured human immunological cell lines. Cell fusion is one method to immortalize desired cells. Therefore, we established HAT sensitive human fusion partners, ICLU-B derived from human burkitt lymphoma, ICLU-T from human T cell acute lymphocytic leukemia, ICLU-E from human eosinophilic leukemia, for efficiently making various human immunological hybridomas. When each fusion partner was fused with human peripheral blood lymphocytes or cord blood lymphocytes, their fusion efficiencies were about 1.3, 0.3 and 0.4 clones per 10(5) fusion partners. Approximately 70% of hybridomas derived from ICLU-B were CD19 positive hybridomas, and approximately 80% of those derived from ICLU-T were CD2 positive hybridomas. The CD4 positive or CD8 positive hybridomas of the CD2 positive were approximately 35% and 15%, respectively. Though approximately 80% of hybridomas derived from ICLU-E were CD2 or CD19 positive hybridomas, phagocytosis was observed in the remaining hybridomas which were both CD2 and CD19 negative. Most obtained hybridomas could proliferate in serum free medium as well as the fusion partners. These results suggested that ICLU-B, -T, -E were useful for making human hybridomas derived from various immunological cells.

[1]  K. Aihara,et al.  HO-323, a human B-lymphoblastoid cell line useful for making human-human hybridomas. , 1986, Cell biology international reports.

[2]  M. Greaves,et al.  Establishment and characterization of a new leukaemic T‐cell line (Peer) with an unusual phenotype , 1980, International journal of cancer.

[3]  A. Telerman,et al.  Human suppressor factors constitutively produced by T-T cell hybridomas: functional and biochemical characterization. , 1989, Hybridoma.

[4]  M. Epstein,et al.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). , 1966, Journal of the National Cancer Institute.

[5]  H. Murakami.  Serum-free media used for cultivation of hybridomas. , 1989, Advances in biotechnological processes.

[6]  M. Maeda-Yamamoto,et al.  Establishment of a human fusion partner for making human T-T hybridomas which can grow in serum free medium. , 1999, Human antibodies.

[7]  A. Bøyum,et al.  Isolation of mononuclear cells and granulocytes from human blood. , 1968 .

[8]  K. Saijo,et al.  Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells. , 1994 .

[9]  P. Lipsky,et al.  Ligation of CD40 influences the function of human Ig-secreting B cell hybridomas both positively and negatively. , 1996, Journal of immunology.

[10]  Koji Yamada,et al.  A new human fusion partner, HK-128, for making human-human hybridomas producing monoclonal IgG antibodies , 1990, Cytotechnology.

[11]  K. James,et al.  Human monoclonal antibody production. Current status and future prospects. , 1987, Journal of immunological methods.

[12]  J. Larrick,et al.  The generation and characterization of human monocyte hybridomas. , 1991, Journal of immunological methods.